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A STATE’S EFFORT TO ENHANCE HEALTH CARE: 
EMPOWERING PHARMACISTS WITH PRESCRIBING AUTHORITY 
ABSTRACT 
High rates of unintended pregnancies and costs associated with them have 
been a concern for the health care system in the U.S. The State of Oregon took 
a unique approach to reduce unintended pregnancy rates within its borders. 
Oregon enacted a statute that authorized pharmacists to prescribe hormonal 
contraceptives, which expanded the scope of practice of pharmacists. This 
Article explores whether states, instead of the Food and Drug Administration 
(FDA), should regulate the scope of practice of health care professionals. This 
Article further explores the impact of Oregon’s law on access to hormonal 
contraceptives, safety of women’s health, and costs for patients or the health 
care system. This Article concludes that Oregon, and states in general, is in a 
better position than the FDA to regulate the practice of health care 
professionals. Also, Oregon’s law will increase access to hormonal 
contraceptives without jeopardizing the safety of women’s health and will not 
increase costs for patients or for the health care system. 
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I.  INTRODUCTION 
Contraception is named as one of the greatest public health achievements of 
the twentieth century by the Centers for Disease Control and Prevention (CDC).1 
Still, however, the rates of unintended pregnancy are higher in the U.S. than in 
most other developed countries.2 Reducing these rates has been identified as a 
national priority by the Department of Health and Human Services (HHS).3 
On January 1, 2016, the State of Oregon took an unprecedented step to 
reduce unintended pregnancy rates within its borders. The state enacted a statute 
that authorized pharmacists to prescribe oral and transdermal contraceptives to 
women aged eighteen years or older.4 This law also allowed pharmacists to 
prescribe to women younger than eighteen years of age who have a previous 
prescription from a primary care provider.5 
Oregon’s new law has raised concerns in the legal and medical communities. 
This law is giving pharmacists an authority to prescribe, a power that 
pharmacists have never exercised before in providing health care. The legal 
community’s concern is whether states, instead of the Food and Drug 
Administration (FDA), have and should be allowed to have the power to expand 
and regulate the practice of health care professionals.6 Through this law, 
pharmacists will be prescribing to millions of women and exercising 
 
 1. See Ten Great Public Health Achievements – United States, 1900–1999, 48 CTRS. FOR 
DISEASE CONTROL & PREVENTION MORBIDITY & MORTALITY WKLY. REP. 241, 241 (1999), 
https://www.cdc.gov/mmwr/preview/mmwrhtml/00056796.htm; see also ADAM SONFIELD ET AL., 
GUTTMACHER INST., THE SOCIAL AND ECONOMIC BENEFITS OF WOMEN’S ABILITY TO 
DETERMINE WHETHER AND WHEN TO HAVE CHILDREN 3 (2013), https://www.guttmacher.org/ 
sites/default/files/report_pdf/social-economic-benefits.pdf (describing benefits of contraception 
and how it has improved family planning for women). 
 2. See Gilda Sedgh et al., Intended and Unintended Pregnancies Worldwide in 2012 and 
Recent Trends, 45 STUD. FAM. PLAN. 301, 306 (2014) (stating that the rates of unintended 
pregnancy have remained significantly higher in the U.S. than in other developed countries for 
many years); see also Wm. Robert Johnston, Abortion Rates by Country (Countries Listed by 
Name), JOHNSTON’S ARCHIVE (Feb. 25, 2017), http://www.johnstonsarchive.net/policy/abortion/ 
wrjp336abrate2.html; GUTTMACHER INST., FACT SHEET: UNINTENDED PREGNANCY IN THE 
UNITED STATES 1 (2019), https://www.guttmacher.org/fact-sheet/unintended-pregnancy-united-
states. 
 3. U.S. Dep’t of Health and Hum. Servs., Healthy People 2020 Summary of Objectives: 
Family Planning, OFF. DISEASE PREVENTION & HEALTH PROMOTION (Mar. 18, 2018), 
http://www.healthypeople.gov/2020/topics-objectives/topic/family-planning/objectives/; see also 
Lawrence B. Finer & Mia R. Zolna, Unintended Pregnancy in the United States: Incidence and 
Disparities, 2006, 84 CONTRACEPTION 478, 478 (2011). 
 4. OR. REV. STAT. § 689.689(1)(a) (2017) (emphasis added). 
 5. OR. REV. STAT. § 689.689(1)(b) (2017). 
 6. See generally Patricia J. Zettler, Pharmaceutical Federalism, 92 IND. L.J. 845, 892 (2017); 
Jesse C. Vivian, Pharmacists Prescribing Birth Control, US PHARMACIST 48, 50 (2016) (stating 
that Oregon is the first state to enact such law and other states are following Oregon, where legality 
of such laws is uncertain). 
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independent treatment judgment that will directly affect women’s health and use 
of hormonal contraceptives in the state. The medical community’s concern is 
that allowing pharmacists to prescribe might not increase access to hormonal 
contraceptives, because women may not be willing to receive prescriptions from 
pharmacists as pharmacists are not used to making independent treatment 
decisions.7 The medical community is also concerned that this law might 
jeopardize safety, because pharmacists are not accustomed to evaluating 
patients’ conditions and treating them with prescription-only drugs.8 This raises 
an additional concern that costs for patients and for the health care system might 
increase. 
However, Oregon’s model offers strong solutions that likely resolve all 
concerns of the legal and medical communities. This article describes these 
solutions by evaluating legal, scientific, and scholarly literature via an 
interdisciplinary approach. Regarding the legal community’s concern, this 
Article proposes that states have the authority to regulate the practice of health 
care professionals, because this power has been granted to them by the 
Fourteenth Amendment and has been acknowledged by the Supreme Court of 
the United States. Moreover, this Article advocates three major reasons that 
demonstrate Oregon, and states in general, is in a better position than the FDA 
to regulate the practice of health care professionals. First, Oregon will be able to 
respond to local access needs of its citizens more effectively and quickly than 
the FDA. Second, Oregon can enact laws that will allow health care 
professionals to address clinical needs of individual patients. Third, Oregon can 
enforce regulations and supervise the practice of health care professionals more 
closely and effectively than the FDA.  
Regarding the medical community’s concerns, this Article proposes that 
Oregon’s model will increase access to hormonal contraceptives. Clinical 
studies have shown that allowing pharmacists to prescribe hormonal 
contraceptives actually increases access, because women are willing and feel 
safe to receive hormonal contraceptive prescriptions from pharmacists. Also, 
this was evident by an increase in sales of hormonal contraceptives in those 
studies. Oregon’s model will not jeopardize safety of women’s health; rather it 
will improve their health. The clinical studies have also proved that pharmacists 
can prescribe medications more safely, in fact, than physicians. Oregon’s model 
 
 7. See FDA Proposal to Allow Pharmacists to Prescribe Some Drugs Sparks Swift Rebuke 
from AAFP, AM. ACAD. OF FAM. PHYSICIANS (May 2, 2012), https://www.aafp.org/news/govern 
ment-medicine/20120502pharmprescribing.html. 
 8. See Sarah Breitenbach, States Start to Let Pharmacists Prescribe Birth Control Pills, PEW 
CHARITABLE TR. (Feb. 18, 2016), http://www.pewtrusts.org/en/research-and-analysis/blogs/state 
line/2016/02/18/states-start-to-let-pharmacists-prescribe-birth-control-pills (stating that 
pharmacists are unable to safely examine women and recommend hormonal contraceptives); see 
also Daisy Contreras, Pharmacist’s Order: Birth Control Without the Doctor, NPR: ILL. (Aug. 9, 
2018), http://www.nprillinois.org/post/pharmacists-order-birth-control-without-doctor#stream/0. 
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will not increase costs for patients or for the health care system. Finally, the 
studies have shown that increasing access to hormonal contraceptives reduces 
unintended pregnancy and abortion rates, which decreases overall health care 
cost. Also, with Oregon’s model, the cost for patients will not increase, because 
prescriptions from pharmacists will be covered by insurance and patients will 
pay nothing or reduced costs for their prescriptions. 
Part II of this Article is divided into two sections. Section A will discuss the 
FDA’s authority in regulating public health. This section will describe the 
FDA’s role and involvement specifically in the drug approval process. Section 
B will discuss congruent authority of states in regulating public health. This 
section will describe states’ roles in supervising the practice of health care 
professionals and also draw a distinction from the FDA’s authority. 
Part III of this Article also is divided into two sections. Section A will 
discuss the history and development of hormonal contraceptives. This section 
will describe the characteristics that led to their prescription-only status. Section 
B will discuss the authority of the FDA to switch a drug from prescription-only 
to non-prescription status and the scientific data it analyzes in making a switch. 
This section will describe the switch of one hormonal contraceptive drug, 
levonorgestrel (Plan B), to non-prescription status and how that impacts the 
public’s access to the drug. 
Part IV of this Article is divided into four sections. Section A will analyze 
Oregon’s new law and its scope pursuant to a state’s power recognized by the 
federal courts. This section will examine whether Oregon, compared to the FDA, 
is in a better position to regulate the practice of health care professionals. Section 
B will discuss the legislative intent behind Oregon’s new law and whether there 
is a need to increase access to hormonal contraceptives. This section will 
investigate whether women are willing to receive hormonal contraceptive 
prescriptions from pharmacists and whether allowing pharmacists to prescribe 
hormonal contraceptives can actually increase access. Section C will analyze the 
impact of Oregon’s new law on safety of women’s health. This section will 
examine whether women feel safe in receiving hormonal contraceptive 
prescriptions from pharmacists and whether pharmacists can prescribe them 
safely. Section D will analyze the impact of Oregon’s new law on costs for 
patients and for the health care system. This section will also discuss whether 
Oregon has taken any measures to reduce the financial burden on patients. 
Part V of this Article will provide an overview of solutions to the legal and 
medical communities’ concerns addressed in Part IV. This section will also 
summarize the authority of states and the FDA in regulating public health and 
will assess whether Oregon is in a better position to regulate the practice of 
health care professionals. This section further will conclude on impact of 
Oregon’s new law on access, safety, and cost of hormonal contraceptive use in 
the state. 
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II.  BACKGROUND REGULATION 
This Part will discuss the congruent power of the FDA and states in 
regulating public health. This Part also will draw a distinction between these 
powers and describe how regulating drugs is reserved to the FDA and regulating 
the practice of health care professionals is reserved to states. 
A. The Food and Drug Administration’s Power to Regulate Drugs 
The FDA is a federal regulatory agency that protects the public by regulating 
the safety, efficacy, and quality of drugs marketed in the country.9 The FDA also 
assures that all necessary information is available to the public for safe use of 
drugs.10 The FDA is well-known for its “gatekeeping” authority for entry of new 
drugs in the market.11 As per 21 U.S.C. § 355(a), “[n]o person shall introduce or 
deliver for introduction into interstate commerce any new drug, unless an 
approval of an application [by the FDA].”12 Thus the FDA is a gatekeeper to 
new drugs, because they cannot be sold or marketed in the U.S. without its 
approval. 
In addition to the authority to supervise entry of new drugs, the FDA also 
has the authority to further restrict their access. The Food, Drug, and Cosmetic 
Act authorizes the FDA to assign ‘prescription-only’ status to drugs upon 
finding that “[the drug’s] toxicity or other potentiality for harmful effect, or the 
method of its use, or the collateral measures necessary to its use, is not safe for 
use except under the supervision of a practitioner licensed by law to administer 
[it].”13 Thus, the FDA can restrict access of certain drugs, making them available 
only via prescription from a licensed practitioner. 
Moreover, the FDA’s authority covers the “entire lifecycle of a drug,” from 
the early stages of research to its approval. To approve a drug for sale in the 
U.S., the FDA must determine that the drug is safe and effective for its proposed 
indication by the manufacturer.14 The safety and effectiveness must be shown 
via “substantial evidence,” which includes data from “adequate and well-
controlled” clinical trials.15 After a manufacturer applies for approval of a drug, 
the FDA and the manufacturer are constantly in communication throughout the 
approval process of the drug.16 The FDA also conducts advisory committee 
meetings, where drug experts can raise concerns regarding the drug.17 The FDA 
 
 9. What We Do, FDA (Mar. 28, 2018), https://www.fda.gov/about-fda/what-we-do. 
 10. Id. 
 11. Zettler, supra note 6, at 857. 
 12. 21 U.S.C. § 355(a) (2012). 
 13. Id. § 353(b)(1). 
 14. Id. § 355(d). 
 15. Id. 
 16. See 21 C.F.R. § 314.102(a) (2016) (stating that the “FDA shall communicate with 
applicants about scientific, medical, and procedural issues that arise during the review process”). 
 17. Id. § 314.103(c)(3). 
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also assures that the proposed labeling is not false or misleading and “good 
manufacturing practice” was used during the development of the drug.18 When 
the FDA decides to approve a new drug, it provides the public with 
comprehensive scientific data that supports its approval decision.19 Thus, the 
FDA’s collaborative and extremely comprehensive new drug approval process 
covers the entire lifecycle of a drug.20 
Despite the intense effort involved in the FDA approval process, the FDA’s 
approval is limited as it does not determine that the drug is “generally” safe and 
effective. Instead, the FDA determines that a drug is safe and effective only for 
a particular use proposed by the manufacturer, that is, to treat a specific 
condition at a particular dose in a certain patient population.21 However, once 
the FDA approves a drug, physicians may prescribe the drug for any other 
conditions, including unapproved uses, known as “off-label” uses.22 
Thus, the FDA is not only a gatekeeper to new drugs, but it also has the 
authority to further restrict access to them. The laws also allow the FDA to be 
actively involved in every step of the drug development and approval process. 
This expansive power of the FDA enables it to regulate public health via its 
supervision at every stage of a drug’s lifecycle. 
B. The States’ Power to Regulate the Practice of Health Care Professionals 
It is a well-established principle, arising from the Supreme Court’s decision, 
that states have the power to regulate the practice of health care professionals. 
In Graves v. State of Minnesota, the Supreme Court stated that “a state may, 
consistently with the Fourteenth Amendment, prescribe that only persons 
possessing the reasonably necessary qualifications of learning and skill shall 
practise [sic] medicine[.]”23 This recognition is based on the rationale that for 
the general welfare of its citizens, a state, in its judgment, is allowed to enact 
laws to regulate the practice of health care professionals to protect its citizens 
from harm caused by the incompetent and unethical practice of health care.24 
In addition, federal courts have distinguished between the congruent 
authority of states and the FDA regarding protecting the public. In United States 
v. Evers, the Fifth Circuit clarified that the FDA was not intended and does not 
have the authority to regulate the practice of health care professionals.25 The 
circuit court further stated that the FDA was only intended to “control the 
 
 18. Id. § 314.125(b)(6), (13). 
 19. Id. § 314.430(e). 
 20. Zettler, supra note 6, at 858. 
 21. See Rebecca Dresser & Joel Frader, Off-Label Prescribing: A Call for Heightened 
Professional and Government Oversight, 37 J. L. MED. & ETHICS 476, 477 (2009). 
 22. Id. at 476, 477. 
 23. Graves v. State of Minn., 272 U.S. 425, 427 (1926). 
 24. Id. 
 25. United States v. Evers, 643 F.2d 1043, 1048 (5th Cir. 1981). 
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availability of drugs” that practitioners could prescribe.26 Similarly, in United 
States v. Regenerative Sciences, LLC, the FDA stated that Congress did not 
intend for the FDA to regulate the practice of health care professionals.27 
Moreover, the court, supporting the FDA’s view, also noted that Congress left 
the practice of health care professionals for states to regulate.28 Thus, the federal 
courts have distinguished between regulation of products and regulation of 
practice. 
This distinction between practice and products serves as the dividing line 
between state and federal regulation. In October 2013, the FDA approved 
Zohydro ER, a new, high-dose opioid medication.29 The State of Massachusetts, 
in an attempt to address opioid addiction problems, prohibited “prescribing and 
dispensing” of Zohydro ER by practitioners within its borders, because this new 
medication lacked abuse-resistant formulation.30 Here, the state’s regulation 
contradicted the FDA’s approval of Zohydro ER to be widely available for 
practitioners throughout the country. The court considered whether Congress 
intended FDA oversight to preempt state regulation and whether Massachusetts 
intended to regulate drugs.31 The court reasoned that FDA’s approval of country-
wide availability of Zohydro ER preempted state regulations.32 The court further 
reasoned that Massachusetts intended to regulate Zohydro ER even though the 
prohibition in the statute technically applied only to practitioners.33 The court 
concluded that the state cannot indirectly regulate medical products via medical 
practice regulations.34 Hence, the federal courts have acknowledged medical 
practice regulation pursuant to states’ police powers and medical product 
regulations pursuant to the FDA’s power. 
However, there are some examples where state regulations have extended 
their reach and entered into the federal drug regulation arena. Over thirty states 
have passed “right-to-try” laws that permit terminally-ill patients access to drugs 
that are unapproved by the FDA.35 At least thirty-four states have enacted laws 
that allow use of marijuana for medical purposes, regardless of whether the FDA 
has approved marijuana for medical purposes or whether such laws are 
 
 26. Id. 
 27. United States v. Regenerative Scis., LLC, 741 F.3d 1314, 1319–20 (D.C. Cir. 2014). 
 28. Id. at 1319. 
 29. Zogenix, Inc. v. Patrick, No. 14-11689-RWZ, 2014 WL 1454696, at *1 (D. Mass. Apr. 
15, 2014). 
 30. Id. 
 31. Id. at *2. 
 32. Id. 
 33. Id. 
 34. Zogenix, 2014 WL 1454696, at *2. 
 35. Melissa Healy, Dying Patients Want Easier Access to Experimental Drugs. Here’s Why 
Experts Say That’s Bad Medicine, L.A. TIMES (Mar. 14, 2017), http://www.latimes.com/science/sci 
encenow/la-sci-right-to-try-medicines-20170314-story.html. 
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consistent with the federal Controlled Substances Act.36 The constitutionality of 
these state regulations still remains uncertain. 
Hence, states have the authority to regulate the practice of health care 
professionals. The federal courts have distinguished and acknowledged medical 
practice regulation as a power reserved to states and medical product regulation 
as a power reserved to the FDA. 
III.  HORMONAL CONTRACEPTIVES 
This part will describe why hormonal contraceptives are assigned 
prescription-only status. This part will also address why the FDA decided to 
assign non-prescription status to Plan B and how that affects the public’s access 
to the drug. 
A. History and Nature of Hormonal Contraceptives 
A hormonal contraceptive, also known as birth control drug, is any pill, 
injection, or device that uses hormones to prevent pregnancy.37 In 1960, the 
FDA approved the first oral contraceptive: a pill containing mestranol and 
norethynodrel.38 This medication became quite popular upon its approval, but 
its high-dose formulation caused blood-clotting problems (like venous 
thromboembolism and arterial vascular events) that led to the increase in 
mortality risk among its users.39 With significant research and development in 
hormone therapy, low-dose, low-risk formulations with estrogen and progestin 
were developed.40 In the 1970s, a progestin-only pill containing norethindrone, 
also known as the mini pill, became widely available in the country.41 The mini 
pill was less effective than previous formulations, because it only contained 
progestin; yet it was considered comparatively safe.42 In the 1990s, hormone 
combination formulations containing estrogen and progestin were developed 
 
 36. State Medical Marijuana Laws, NAT’L CONF. ST. LEGISLATURES (March 5, 2019), 
http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. 
 37. Hormonal Birth Control, LEXICOMP ONLINE (Oct. 11, 2017), http://www.crlonline.com/ 
lco/action/doc/retrieve/docid/disandproc/4147842 (source on file with author). 
 38. Frank B. Colton, Steroids and “The Pill”: Early Steroid Research at Searle, 57 STEROIDS 
624, 628 (1992). 
 39. Risk of Thromboembolic Disease in Women Taking Oral Contraceptives: A Preliminary 
Communication to the Medical Research Council by A Subcommittee, 2 BRIT. MED. J. 355, 359 
(1967). 
 40. W. H. W. Inman et al., Thromboembolic Disease and the Steroidal Content of Oral 
Contraceptives: A Report to the Committee on Safety of Drugs, 2 BRIT. MED. J. 203, 204, 207 
(1970) (describing how combined regimens of estrogen and progestogen were developed). 
 41. Diana B. Petitti & Stephen Sidney, Four Decades of Research on Hormonal 
Contraception, 9 PERMANENTE J. 29, 29, 31 (2005); Types of Birth Control Pills, EMEDEXPERT, 
https://www.emedexpert.com/classes/birth-control-types.shtml (last visited Apr. 13, 2019). 
 42. See James Trussell, Contraceptive Failure in the United States, 83 CONTRACEPTION 397, 
399, 401 (2011). 
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(containing one-third to one-fifth of the amount of estrogen and various amounts 
of progestin).43 
Most hormonal contraceptives now contain both progestin and estrogen.44 
Progestin suppresses ovulation by prohibiting the surge of follicle-stimulating 
hormone and luteinizing hormone, thickening cervical mucus, and keeping the 
endometrium lining thin.45 Estrogen also suppresses ovulation in the ovaries and 
prevents breakdown of the endometrium lining in the uterus.46 Thus, progestin 
and estrogen together in hormonal contraceptives work to make the uterus 
inhospitable for implantation of a fertilized egg, and thereby prevent pregnancy. 
Hormonal contraceptives come in various formulations: pills, patches, 
vaginal rings, injections, implants, and intrauterine devices (IUDs).47 Selection 
of the appropriate formulation for a particular patient requires medical judgment, 
as each of these formulations has different dosing schedules and mechanisms of 
function. With oral pills, practitioners recommend women take a pill every day; 
women who prefer not to get a period are recommended to skip the hormone-
free pills in the pack and take a hormone pill every day instead.48 With skin 
patches, practitioners recommend women wear the patch on the upper arm, 
shoulder, back, or hip for three weeks (a new patch each week), and then leave 
the patch off during week four when they have their period.49 With vaginal rings, 
practitioners recommend women put the hormonal ring in the vagina for three 
weeks at a time and remove the ring during week four.50 With injections, 
practitioners give a hormone shot to women in the arm or buttocks every four 
months.51 With implants, practitioners inject a tiny rod in the arm that releases 
hormones, and the rod can stay in the arm for up to three years.52 With IUDs, 
practitioners place a device inside the uterus that releases hormones.53 Thus, 
selection and use of hormonal contraceptives is done under direct supervision 
and direction of health care practitioners. 
Hormonal contraceptives interact with many common medications, and 
practitioners will check such interactions before prescribing particular 
contraceptives. Hormonal contraceptives interact with rifamycin-class 
antibiotics like rifampin, rifabutin, rifapentine; anti-seizure medications like 
 
 43. Petitti & Sidney, supra note 41, at 32. 
 44. Hormonal Birth Control, supra note 37. 
 45. Kathryn A. Martin & Robert L. Barbieri, Overview of the Use of Estrogen-Progestin 
Contraceptives, UPTODATE (Sept. 25, 2018), https://www.uptodate.com/contents/overview-of-
the-use-of-combined-estrogen-progestin-oral-contraceptives (source on file with author). 
 46. Id. 
 47. Hormonal Birth Control, supra note 37. 
 48. See Martin & Barbieri, supra note 45. 
 49. Hormonal Birth Control, supra note 37. 
 50. Id. 
 51. Id. 
 52. Id. 
 53. Id. 
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barbiturates, carbamazepine, phenytoin; antiviral medications containing 
ritonavir; and herbal remedies such as St. John’s wort.54 These interactions can 
reduce the efficacy of either the hormonal contraceptives or of the additional 
medication.55 The interactions are significant enough to warrant intervention by 
a practitioner of either a different approach to contraception or a different 
medication for the underlying condition.56 Thus, interactions of hormonal 
contraceptives with numerous drugs require them to be prescribed under the 
supervision of an experienced health care practitioner. 
Moreover, hormonal contraceptives require careful assessment of medical 
history of a patient. Before prescribing, practitioners generally measure the 
patient’s blood pressure and also calculate the patient’s body mass index, 
because obese patients are at greater risk for blood-clotting side-effects (venous 
thromboembolism) of hormonal contraceptives.57 Practitioners also assess for 
symptoms of blood-clotting diseases like chest pain, shortness of breath, and 
cough.58 They also look for new or worsened migraines or headaches associated 
with neurologic signs like confusion, dizziness, and visual disturbances, which 
prohibit use of hormonal contraceptives and warrant evaluation of the 
underlying condition.59 While breast exams, Pap smears, and screening for 
sexually transmitted diseases are important, many professional medical groups, 
including the American College of Obstetricians and Gynecologists and the 
World Health Organization, suggest that these procedures are unnecessary 
before the first prescription.60 Hence, prescription of hormonal contraceptives 
requires appropriate evaluation of medical history and health of a patient by a 
practitioner. 
Therefore, research in hormonal contraceptives has been moving toward 
development of low-risk, low-dose formulations. Hormonal contraceptives must 
be prescribed and dispensed under the supervision of a health care provider, 
because professional medical judgment is warranted for selection of 
formulation, evaluation of drug-interactions, and assessment of patients’ 
medical and contraceptive history. 
 
 54. See Martin & Barbieri, supra note 45. 
 55. Id. 
 56. See id.; Dawn Stacey, 10 Medications That Decrease Your Hormonal Contraception 
Effectiveness, VERYWELL HEALTH (Mar. 27, 2019), https://www.verywellhealth.com/medications-
that-can-cause-interactions-with-the-pill-906876. 
 57. US Selected Practice Recommendations for Contraceptive Use, 2016, CTRS. FOR DISEASE 
CONTROL & PREVENTION (Feb. 1, 2017), https://www.cdc.gov/reproductivehealth/contraception/ 
mmwr/spr/combined.html. 
 58. Id. 
 59. Id.; Migraine Headaches, JOHN HOPKINS MED., https://www.hopkinsmedicine.org/health 
library/conditions/nervous_system_disorders/migraine_headaches_85,P00814 (last visited Apr. 2, 
2019) (describing signs and symptoms of migraines). 
 60. US Selected Practice Recommendations for Contraceptive Use, 2016, supra note 57. 
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B. Plan B: From Prescription-Only to Non-Prescription 
The FDA has authority to assign “non-prescription” status to a drug. As per 
21 U.S.C. § 353(b)(3), the FDA can “remove drugs subject to [prescription-only 
requirements] . . . when such requirements are not necessary for the protection 
of the public health.”61 The FDA can switch only where the evidence 
demonstrates that the drug’s dispensing requirements are no longer “necessary 
for the protection to public health” due to its toxicity or its potential side effects 
and that the drug is safe and effective for the proposed self-use, without 
supervision of a practitioner.62 Thus, the FDA can switch a drug from 
prescription-only to non-prescription status. 
Levonorgestrol, currently marketed as Plan B, is an emergency 
contraceptive that was recently switched to non-prescription status by the FDA, 
increasing women’s access to it. Emergency contraceptives are hormonal 
contraceptives that are used to prevent pregnancy when taken within seventy-
two hours after unprotected sex.63 Many professional medical groups, including 
the American Medical Association and the Association of Reproductive Health 
Professionals, advocated for making levonorgestrel available as a non-
prescription drug.64 Levonorgestrel was well tolerated and safe based on the 
extensive safety data from clinical studies where more than 15,000 women took 
various doses of it for emergency contraception.65 Moreover, the data collected 
from comprehensive research in literature and unpublished study reports did not 
uncover any major side effects.66 There were no serious adverse events reported 
during the ongoing studies or from introductory trials that were related to the use 
of levonorgestrel.67 Also, no major side effects, such as thromboembolic events 
or ectopic pregnancies, were reported with these studies, a concern that exists 
with all prescription-only hormonal contraceptives.68 Therefore, based on 
scientific data from clinical trials, there was no medical reason to restrict 
levonorgestrel to prescription-only status. 
 
 61. 21 U.S.C. § 353(b)(3) (2012). 
 62. See id.; 21 C.F.R. 310.200(b) (2016). 
 63. Heather M. Field, Comment, Increasing Access to Emergency Contraceptive Pills through 
State Law Enabled Dependent Pharmacist Prescribers, 11 UCLA WOMEN’S L. J. 141, 147 (2000). 
 64. Louis Cantilena, Coalition Letter to the USFDA Urging the Nonprescription Drugs 
Advisory Committee to Change the Status of Emergency Contraceptive from Rx to Over-the-
Counter, ACLU, https://www.aclu.org/letter/coalition-letter-usfda-urging-nonprescription-drugs-
advisory-committee-change-status (last visited Apr. 5, 2019). 
 65. See CTR. FOR DRUG EVALUATION & RESEARCH, APPROVAL PACKAGE FOR: 
APPLICATION NUMBER: NDA 021998/S-002 63–75 (2013), https://www.accessdata.fda.gov/drugs 
atfda_docs/nda/2013/021998Orig1s002.pdf. 
 66. Id. at 1. 
 67. Id. at 40 (noting “miscarraige is a common outcome of pregnancy and the relationship of 
this event to [levonorgestrel] could not be definitely established.”). 
 68. Id. at 59. 
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Levonorgestrol’s switch to non-prescription status was achieved in a quite 
controversial manner, signifying the FDA’s difficulty in regulating hormonal 
contraceptives and the public’s interest in availability of these drugs.69 In 
February 2011, Teva Pharmaceuticals submitted an application to make 
levonorgestrel available as non-prescription.70 In December 2011, the FDA was 
set to approve non-prescription status with no age restriction based on the studies 
submitted by Teva.71 However, this action was overruled by the Secretary of 
HHS.72 Teva then filed an amended application with additional substantial 
data.73 The Center for Reproductive Rights filed a lawsuit against the Secretary 
in the federal district court of New York for overruling on the FDA’s decision.74 
In April 2013, the court ordered the FDA to allow over-the-counter sales of 
levonorgestrel with no age restriction.75 The court stated that “the secretary’s 
action was politically motivated, scientifically unjustified, and contrary to 
agency precedent.”76 In June 2013, levonorgestrel became available as a non-
prescription drug without age restriction and is marketed as Plan B throughout 
the country.77 In most pharmacies, it is located on the shelf in the family 
planning aisle; some pharmacies may choose to keep it in a locked cabinet.78 
Hence, the FDA has authority to switch a drug to non-prescription status. 
Plan B is an example of a hormonal contraceptive that was recently switched to 
non-prescription status by the FDA, making it available as an over-the-counter 
medication for women. 
IV.  OREGON MODEL’S IMPLICATIONS 
This Part will analyze the scope of Oregon’s new law and describe whether 
Oregon, and states in general, is in a better position to regulate practice of health 
care professionals compared to the FDA. This Part further will examine whether 
allowing pharmacists to prescribe hormonal contraceptives can actually increase 
access to such drugs. Moreover, this Part will investigate whether women feel 
safe in receiving hormonal contraceptive prescriptions from pharmacists and 
whether pharmacists can prescribe them safely. Finally, this Part will assess 
 
 69. See Alexandra Sifferlin, Timeline: The Battle for Plan B, TIME (June 11, 2013), 
http://healthland.time.com/2013/06/11/timeline-the-battle-for-plan-b/. 
 70. See CTR. FOR DRUG EVALUATION & RESEARCH, supra note 65; Sifferlin, supra note 69. 
 71. Sifferlin, supra note 69. 
 72. Id. 
 73. See id. 
 74. See Tummino v. Hamburg, 936 F. Supp. 2d 162, 164, 194 (E.D.N.Y. 2013). 
 75. Id. at 197. 
 76. See id. at 192. 
 77. See Sifferlin, supra note 69. 
 78. Diana Yap, Plan B One-Step Now on Store Shelves, AM. PHARMACISTS ASS’N (Aug. 20, 
2013), http://pharmacist.com/plan-b-one-step-now-store-shelves. 
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whether Oregon’s new law increases costs for patients and for the health care 
system. 
A. Oregon’s Power to Regulate the Practice of Health Care Professionals 
Oregon enacted a statute, section 689.683(1) of the Oregon Revised Statute, 
which went into effect on January 1, 2016 and expanded the scope of the practice 
of pharmacists. The statute provides that pharmacists can prescribe and dispense 
self-administered hormonal contraceptives.79 The statute authorizes pharmacists 
to prescribe two formulations of hormonal contraceptives: oral pills and patches. 
A pharmacist cannot prescribe other formulations such as injections, IUDs, and 
implants, as discussed in Part II, Section A. The statute further states that “a 
pharmacist may prescribe . . . hormonal contraceptive patches and self-
administered oral hormonal contraceptives to a person who is: (a) [a]t least 18 
years of age . . .; or (b) [u]nder 18 years of age, only if the person has evidence 
of a [such] previous prescription from a primary care practitioner . . . .”80 
Essentially, the statute poses age requirements where patients younger than 
eighteen years of age cannot receive a prescription from a pharmacist without a 
previous prescription from a primary care provider. “This caveat ensures that 
women will still receive the recommended screenings,” like a Pap test for their 
first prescription from primary care providers.81 However, patients who are 
younger than eighteen years of age are not completely deprived of receiving 
hormonal contraceptives. They still can receive their first prescription from a 
primary care provider. Primary care providers also have the authority to 
prescribe hormonal contraceptives, and Oregon’s practice of medicine statute 
does not pose any age limitations on hormonal contraceptives.82 Interestingly, 
this expanded scope of the practice of pharmacy overlaps with the scope of the 
practice of medicine at least on the part of prescribing oral and transdermal 
hormonal contraceptives. 
Oregon’s new law only regulates the practice of pharmacy, a role for states 
that the Supreme Court has acknowledged as constitutional. The Court has 
determined that states are granted power to regulate the practice of health care 
professionals through the Fourteenth Amendment.83 The expanded scope of the 
practice of pharmacists in Oregon does not contradict the FDA’s approval of 
hormonal contraceptives. This lies in contrast to Zogenix, Inc. v. Patrick, 
discussed in Part II, Section B, where Massachusetts attempted to prohibit the 
 
 79. OR. REV. STAT. ANN. § 689.683(1) (West 2016) (amended 2017). 
 80. Id. 
 81. Erin N. Deja & Joseph L. Fink III, Pharmacists Prescribing Birth Control: Improving 
Access and Advancing the Profession, PHARMACY TIMES (Nov. 16, 2016), http://www.pharmacy 
times.com/publications/issue/2016/november2016/pharmacists-prescribing-birth-control-improv 
ing-access-and-advancing-the-profession. 
 82. See OR. REV. STAT. § 677.089 (2017). 
 83. Graves v. Minnesota, 272 U.S. 425, 427 (1926). 
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use of an FDA-approved drug in the state and made the drug completely 
unavailable for its citizens.84 The court held Massachusetts’s law invalid, 
because it was regulating drugs contrary to FDA’s decision, that is, what 
physicians can or cannot prescribe.85 Here, Oregon is not prohibiting or 
disapproving the use of FDA-approved hormonal contraceptives within its 
borders. It is only regulating who can prescribe them, particularly providing 
pharmacists with such authority, and not what practitioners can or cannot 
prescribe. Hence, this regulation does not regulate drugs and clearly falls within 
regulating the practice of health care professionals. Also, the FDA’s 
determination that hormonal contraceptives be prescribed under supervision of 
a practitioner is not contradicted by Oregon’s new law, because hormonal 
contraceptives are still required to be prescribed under the supervision of a 
pharmacist.86 
In fact, there are some examples where states have expanded the scope of 
the practice of pharmacists. In Florida, a pharmacist can prescribe otic 
analgesics, anti-nausea preparations, and topical antibacterials from a formulary 
defined in the statute.87 In California, a pharmacist can prescribe emergency 
contraception drugs, nicotine replacement products, and “medications not 
requiring a diagnosis . . . for individuals traveling outside of the United 
States.”88 Thus, some states have expanded the scope of the practice of 
pharmacists where they can prescribe medications from approved formularies. 
Oregon, and states in general, is in better position than the FDA to expand 
and regulate the practice of health care professionals for three major reasons. 
First, Oregon will be able to serve its citizens more effectively than the FDA, 
because Oregon has the expertise to understand local needs of its citizens and 
can quickly respond to challenges with new laws if need be. Even though it is 
suggested that such state experimentation may threaten public health,89 the 
needs of the citizens might worsen with the FDA regulation of pharmacists, 
because it would be too expansive in scope, missing specific details required to 
address local needs, and be oppressive and binding on other states.  
 
 84. Zogenix, Inc. v. Patrick, No. 14-11689-RWZ, 2014 WL 1454696, at *1 (D. Mass. Apr. 
15, 2014). 
 85. See id. at *2–3 (emphasis added). 
 86. Pharmacists are recognized as health care providers in Oregon. See OR. REV. STAT. 
§ 689.295 (2017); Loren Bonner, Pharmacist Provider Status Now Law in Oregon, PHARMACY 
TODAY (July 28, 2015), https://www.pharmacist.com/article/pharmacist-provider-status-now-law-
oregon. 
 87. FLA. STAT. § 465.186 (2018); FLA. ADMIN. CODE ANN. r. 64B16-27.220 (2007). 
 88. CAL. BUS. & PROF. CODE § 4052(a)(10) (2018). 
 89. See Robert L. Glicksman & Richard E. Levy, A Collective Action Perspective on Ceiling 
Preemption by Federal Environmental Regulation: The Case of Global Climate Change, 102 NW. 
U. L. REV. 579, 594–600 (2008). 
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Second, allowing the FDA to govern the practice of pharmacists may restrict 
pharmacists’ flexibility in successfully carrying out their duties and obligations 
to their patients. The FDA regulation may force pharmacists to provide care not 
based on their judgment of an individual patient’s best interests, but instead 
based on overall public health objectives.90 For instance, the federal Drug 
Enforcement Agency’s current restrictions on the use of certain opioid drugs, 
aimed at reducing opioid drug abuse nationally, make it challenging for 
practitioners to treat patients that have genuine medical needs.91 
Third, because the FDA lacks state-specific focus and maintains general 
nationwide presence, the FDA’s enforcement of pharmacists’ practice in Oregon 
specifically would become challenging. There is evidence that federally 
regulating the practice of health care professionals has been unsuccessful. For 
example, an estimated thirty percent of human growth hormone drugs prescribed 
by physicians is for off-label uses that are not approved by the FDA.92 On the 
other hand, there is an argument that federal supervision is required in many 
cases. For instance, in April 2011, Colorado identified adulterated drugs 
compounded by a Massachusetts’s pharmacy and blocked their sales in the 
state.93 Even though Colorado had promptly notified Massachusetts, 
Massachusetts was unable to stop the adulterated drugs from reaching and 
harming patients in other states.94 In this case, it is likely that the FDA’s 
supervision over compounding practices could have prevented the production of 
adulterated drugs. 
It is true that for certain problems uniform policy and federal supervision is 
necessary;95 however, in cases where patient-specific and local needs are 
considered, like women’s access to certain federally-approved drugs, states 
should have the authority to regulate. Federal regulation is generally warranted 
when health care practice within states contributes to a national public health 
concern that the states are unable to address.96 When the states have already 
established coherent measures to regulate the practice of health care 
professionals effectively, then there should be no need for federal agencies to 
intervene.97 
 
 90. See Patricia J. Zettler, Toward Coherent Federal Oversight of Medicine, 52 SAN DIEGO 
L. REV. 427, 487 (2015). 
 91. See Veterans Complain New Painkiller Rules Increase Their Suffering, SFGATE (Feb. 18, 
2015), https://www.sfgate.com/nation/article/Veterans-complain-new-painkiller-rules-increase-60 
88081.php. 
 92. Mary Lee Vance, Can Growth Hormone Prevent Aging?, 348 NEW ENG. J. MED. 779, 780 
(2003). 
 93. Kevin Outterson, The Drug Quality and Security Act—Mind the Gaps, 370 NEW ENG. J. 
MED. 97, 97 (2014). 
 94. Id. 
 95. Zettler, supra note 90, at 481. 
 96. Id. at 482. 
 97. Id. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
382 SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY [Vol. 12:367 
B. Impact on Access to Hormonal Contraceptives 
In a news release on May 27, 2015, the Chair of Oregon Legislature Rules 
Committee, Val Hoyle, stated that “[i]ncreasing access to birth control is one of 
the most important things we can do to improve the lives and health of women 
from all walks of life.”98 She further stated that “[w]e all share the goal of 
reducing the number of unwanted pregnancies, and one of the most effective 
ways we can do that is to increase access and availability of contraceptives for 
women across the state from every background.”99 The legislative intent behind 
Oregon’s new law is to increase access for women to hormonal contraceptives 
in the state in order to reduce unintended pregnancies. Oregon’s new law 
attempts to achieve this goal by making it easier for women to obtain hormonal 
contraceptive prescriptions directly from pharmacy stores as compared to 
scheduling an appointment and waiting to receive a prescription from a primary 
care provider. 
A qualitative study was conducted with twenty reproductive health 
practitioners, including physicians and advanced practice clinicians, in 
California from 2008 to 2009.100 The study concluded that most providers 
considered prescription-only access to hormonal contraceptives to be too 
restrictive.101 The providers suggested that the rates of unintended pregnancies 
can be reduced by increasing access to hormonal contraceptives through 
pharmacists via education and training.102 
With Oregon’s new law, based on the increase in the number of prescribers, 
it is clear that more health care professionals will now be able to prescribe 
hormonal contraceptives, because along with primary care providers, 
pharmacists can also now prescribe them. However, research data needs to be 
analyzed to determine whether women are willing to receive prescriptions from 
pharmacists and whether allowing pharmacists to prescribe can actually increase 
access to hormonal contraceptives. 
A survey was conducted across the country to better understand women’s 
experiences with hormonal contraceptives and their interest in gaining direct 
access to them. In this study, a telephone survey was conducted in the U.S. on 
 
 98. Scott Moore, House Rules Committee Advances Bill Allowing Pharmacists to Prescribe 
Birth Control, LUND REP. (May 27, 2015), https://www.thelundreport.org/content/house-rules-
committee-advances-bill-allowing-pharmacists-prescribe-birth-control. 
 99. Oregon House Votes to Expand Access to Birth Control, OR. LEGISLATURE (June 2, 2015), 
https://www.oregonlegislature.gov/housedemocrats/Documents/Pharmacy%20Birth%20Control
%20Press%20Release.pdf. 
 100. Sally Rafie et al., Direct Pharmacy Access to Hormonal Contraception: California 
Physician and Advanced Practice Clinician Views, 86 CONTRACEPTION 687, 688–89 (2012). 
 101. Id. at 689. 
 102. Id. at 692. 
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811 women aged 18–44 years who were at risk for unintended pregnancy.103 
The survey looked at women’s readiness and comfort with obtaining hormonal 
contraceptives from pharmacists without first visiting a clinic or a physician.104 
The results showed that sixty-eight percent of women in the U.S. said they will 
use a pharmacy to access hormonal contraceptives.105 Likely users included 
women not using contraception who would begin using hormonal contraceptives 
(forty-one percent) if they were available directly in pharmacies, and oral pills, 
patch, or ring users (sixty-six percent) were interested in obtaining their method 
from pharmacies.106 Thus, most women are willing to receive hormonal 
contraceptive prescriptions from pharmacists. 
The result of the above survey was evident in a pilot study conducted in 
Washington state. Five organizations––Program for Appropriate Technology in 
Health, the Washington State Pharmacists Association, the University of 
Washington Department of Pharmacy, the Washington State Board of 
Pharmacy, and DDB World-wide Communications Group, Inc.—conducted a 
pilot project from February 1998 to June 1999 that allowed pharmacists to 
prescribe hormonal contraceptives. 107 The study measured the number of 
prescriptions sold and demand for hormonal contraceptives.108 During this 
period, emergency contraceptives held prescription-only status. In this project, 
a total of 11,969 prescriptions for emergency contraceptive medications were 
prescribed and dispensed by pharmacists at 130 pharmacies.109 From February 
1998 through December 2000, Washington state pharmacists reported having 
served 28,649 women and more than 1,000 new emergency contraceptive 
prescriptions were initiated by pharmacists per month.110 Hence, this study 
proved that allowing pharmacists to prescribe contraceptives significantly 
increased women’s access to hormonal contraceptives. 
Thus, research data has shown that women are willing to receive 
prescriptions from pharmacists and that allowing pharmacists to prescribe 
hormonal contraceptives has actually increased women’s access to the drugs. 
 
 103. Sharon Cohen Landau et al., Birth Control Within Reach: A National Survey on Women’s 
Attitudes Toward and Interest in Pharmacy Access to Hormonal Contraception, 74 
CONTRACEPTION 463, 464 (2006). 
 104. Id. 
 105. Id. at 467. 
 106. Id. 
 107. Jacqueline S. Gardner et al., Increasing Access to Emergency Contraception Through 
Community Pharmacies: Lessons from Washington State, 33 FAM. PLAN. PERSP. 172, 172 (2001). 
 108. Id. 
 109. Id. 
 110. Id. at 174 (emphasis added). 
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C. Impact on Safety of Prescribed Hormonal Contraceptives 
Many people place substantial trust in pharmacists because of their expertise 
in counseling on proper drug use and knowledge on drug interactions.111 
Pharmacists are also trained in optimizing drug therapy for patients suffering 
from chronic conditions.112 In fact, the FDA proposed to establish a new 
category of drugs that would allow pharmacists to dispense prescription-only 
drugs without a prescription after pharmacists’ intervention as a condition for 
safe use.113 The rationale was that since pharmacists counsel patients on proper 
use of prescription-only drugs, they should also be allowed to dispense them for 
certain chronic medical conditions such as asthma, high blood pressure, and high 
cholesterol, as these conditions are highly undertreated.114  
Even though pharmacists’ image and education seem promising, an inquiry 
needs to be made whether women feel safe in receiving prescriptions from 
pharmacists and whether pharmacists can prescribe hormonal contraceptives 
safely. A community-based intervention study was conducted from 2003 to 2005 
in Seattle, Washington that assessed whether women consider it safe to receive 
hormonal contraceptive prescriptions from pharmacists.115 In this study, 214 
women and 26 community pharmacists participated.116 The participating women 
provided their medical and contraceptive history, and the participating 
pharmacists identified women at risk of unintended pregnancies, measured their 
weight and blood pressure, and prescribed them hormonal contraceptives.117 The 
results showed that 195 women (ninety-one percent) were prescribed hormonal 
contraceptives by pharmacists, and 136 women (seventy percent) reported 
continuing use of hormonal contraceptives.118 Nearly all women expressed 
willingness to continue to see pharmacists for prescriptions and felt safe in 
receiving prescriptions from pharmacists.119 The study also concluded that 
pharmacists can effectively prescribe hormonal contraceptives to women.120 
 
 111. Robert Glatter, Should Pharmacists Prescribe Prescription Medications?, FORBES (May 
11, 2012), https://www.forbes.com/sites/robertglatter/2012/05/11/should-pharmacists-prescribe-
prescription-medications/#5b191b825fcc. 
 112. See, e.g., Pharm. D. Curriculum, OR. ST. U. C. OF PHARMACY, http://pharmacy.oregon 
state.edu/pharm-d-curriculum (last visited Apr. 5, 2019). 
 113. AM. PHARMACISTS ASS’N, 2013 HOUSE OF DELEGATES REPORT OF THE POLICY 
COMMITTEE: REVISIONS TO THE MEDICATION CLASSIFICATION SYSTEM ENSURING ACCESS TO 
PHARMACISTS’ SERVICES MEDICATION TAKE BACK/DISPOSAL PROGRAMS 8 (2013). 
 114. Glatter, supra note 111. 
 115. Jacqueline S. Gardner et al., Pharmacist Prescribing of Hormonal Contraceptives: Results 
of the Direct Access Study, 48 J. AM. PHARMACISTS ASS’N 212, 212 (2008). 
 116. Id. 
 117. Id. 
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Thus, there is evidence that women feel safe in receiving prescriptions from 
pharmacists. 
Moreover, a fourteen-month study was conducted in California that 
compared prescribing abilities of pharmacists and physicians.121 The patients 
were assigned one of two groups, one treated by pharmacists and the other by 
physicians.122 There was no significant difference between the two patient 
populations.123 The study assessed prescribing abilities in six different 
measures: (1) was the chosen drug appropriate for diagnosis; (2) are drug 
interactions properly checked; (3) was quantity appropriately prescribed; (4) was 
the dose proper; (5) were patient directions clear and safe; and (6) will the 
prescription have a positive effect on the patient’s health.124 Pharmacists and 
physicians prescribed from a formulary containing more than 300 drugs like 
antihypertensives, antidiabetics, and thyroid medications.125 The results 
revealed that in measure one, pharmacists scored better than the physicians in 
choosing drugs most appropriate for the diagnosis, with the difference being 
statistically significant (p<0.01, t=-2.61).126 In measures two, three, four, and 
five, although the difference was not statistically significant, pharmacists had 
better scores than physicians.127 In fact, in measure six, which assessed whether 
the prescription would have a positive effect on the patient’s health, pharmacists 
received better scores than physicians with the difference being statistically 
significant (p<0.05, t=-2.51).128 The study concluded that because of 
pharmacists’ expertise in pharmacology and rational drug use, pharmacists can 
prescribe at least as well as, and on some measures, more appropriate than 
physicians.129 Thus, there is evidence that pharmacists can prescribe 
medications safely. 
When it comes to hormonal contraceptives, there is less complication 
involved in making prescribing decisions than with other prescription-only 
drugs. Other prescription-only drugs, such as antihypertensives, antidiabetics, 
thyroid medications, etc., require complex clinical tests like electrolyte levels, 
blood sugar levels, blood hormone levels, and complete blood counts before they 
are prescribed.130 In comparison, hormonal contraceptives only require 
 
 121. William F. McGhan et al., A Comparison of Pharmacists and Physicians on the Quality 
of Prescribing for Ambulatory Hypertensive Patients, 21 MED. CARE 435, 437 (1983). 
 122. Id. at 439. 
 123. Id. at 441. 
 124. Id. 
 125. Id. at 438–39. 
 126. McGhan et al., supra note 121, at 442–44. 
 127. Id. 
 128. Id. 
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 130. AM. C. OF CARDIOLOGY, 2017 GUIDELINE FOR THE PREVENTION, DETECTION, 
EVALUATION, AND MANAGEMENT OF HIGH BLOOD PRESSURE IN ADULTS 1, 13 (2017); AM. 
DIABETES ASS’N, Standards of Medical Care in Diabetes–2017, 40 DIABETES CARE 1, S66–69 
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measurement of weight, BMI, and blood pressure before prescribing.131 Other 
prescription-only drugs are required to be dose-adjusted based on fluctuating 
blood pressure, electrolyte levels, and hormone levels.132 In contrast, hormonal 
contraceptives do not require daily monitoring of clinical health status and are 
not dose-adjusted.133 Also, hormonal contraceptives do not have more drug 
interactions or a more severe side effect profile compared to most other 
prescription-only drugs.134 As shown in the study mentioned previously and also 
corroborated by other studies, pharmacists have safely prescribed more-intense 
and less-safe prescription-only drugs to patients. 135 Thus, pharmacists are 
professionally competent to prescribe hormonal contraceptives safely. 
In addition to the expertise pharmacists already possess, Oregon has 
established training requirements for pharmacists to ensure safe prescribing of 
hormonal contraceptives. Pharmacists throughout the state are required to 
complete a certification course before they are allowed to prescribe hormonal 
contraceptives.136 This course is developed under the guidance of the Oregon 
Board of Pharmacy and accredited by the Accreditation Council for Pharmacy 
Education.137 The program provides a stronger foundation on formulations and 
risks of hormonal contraceptives, educates pharmacists on counseling patients 
in missed pill situations, and teaches pharmacists to assess patients’ eligibility 
for a prescription.138 Moreover, a questionnaire and an algorithm, drafted by the 
Oregon Board of Pharmacy, can be used by pharmacists to obtain adequate 
medical and contraceptive history. The questionnaire asks a patient to state her 
name, health care provider, date of birth, date of last health clinic visit, and 
 
(Supp. I 2017); AM. THYROID ASS’N, 2016 American Thyroid Association Guidelines for 
Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis, 30 THYROID 
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note 57. 
 132. AM. C. OF CARDIOLOGY, supra note 130, at 13; AM. DIABETES ASS’N, supra note 130, at 
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 134. Martin & Barbieri, supra note 45, at 6. 
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 138. Id. 
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health insurance status.139 There are also questions related to the patient’s 
medical and family history.140  
Following the prescribing and dispensing of the hormonal contraceptive, the 
pharmacist must give the patient a “Pharmacist Referral and Visit Summary” 
form.141 When the patient is prescribed a medication, the form will state “Today 
you were prescribed the following hormonal contraceptive” and name the 
medication.142 If the patient is not eligible for a prescription, the form will state 
that “I am not able to prescribe hormonal contraception to you today,” and list 
three possible reasons: (1) the patient has a health condition that requires further 
evaluation, (2) the patient takes medications that may interfere with hormonal 
contraceptives, or (3) the patient’s blood pressure is greater than 140/90 
mmHg.143 Thus, Oregon has developed effective training and procedural 
measures to ensure that hormonal contraceptives are prescribed safely. 
The results of clinical studies show that women feel safe in receiving 
prescriptions from pharmacists. Pharmacists can prescribe at least as safely, and 
in some aspects, more appropriately than physicians. Also, the training and 
procedural requirements established by Oregon further strengthen the safety 
measures. 
D. Impact on Costs for Patients and for the Health Care System 
The cost of unintended pregnancies on the health care system is extremely 
high. Births from unintended pregnancies resulted in approximately twenty-one 
billion dollars in government expenditures in 2010.144 Women with unintended 
pregnancy must either choose to deliver the baby, undergo abortion, or plan for 
adoption; each of these choices involves significant cost for a woman and for 
the health care system. As a result, it is proposed that increasing access to 
contraceptives could reduce the cost for the health care system. Based on recent 
estimates, each dollar spent on publicly-funded contraceptive services will likely 
save $5.68 for the health care system.145  
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A sixteen-month pilot project was conducted in Washington, D.C., that 
assessed the cost for patients and for the health care system from increased 
availability of hormonal contraceptives. In this study, pharmacists prescribed 
hormonal contraceptives to patients.146 The cost per visit averaged between 
thirty and forty dollars, which included contraceptive pills, a medication to 
prevent nausea and vomiting, and the pharmacist’s time in assessing, counseling, 
and documenting interventions.147 With this study, however, there was no third-
party payment service for contraceptive prescriptions.148 Despite no third-party 
financial support, thousands of women paid out-of-pocket to use pharmacists’ 
services.149 This study concluded that provision of hormonal contraceptive 
prescriptions by pharmacists was a cost-saving measure under all assumptions 
for prospective public and private payers.150 This study also reported a decline 
in unintended pregnancies in Washington, D.C., as abortions rates had reached 
the lowest level in two decades, dropping by five percent, and teenage pregnancy 
rates were seven percent lower during the study period.151 Thus, there is 
evidence that increasing access to hormonal contraceptives through pharmacists 
reduces unintended pregnancies. 
Oregon has taken several measures to ensure that excessive financial burden 
on patients is avoided. In Oregon, under the new law, hormonal contraceptive 
prescriptions from pharmacists are covered by insurance.152 Under a separate 
law, health plans must pay for up to a three-month supply for the first fill and up 
to a twelve-month supply for these prescriptions.153 Moreover, Oregon has also 
passed the “pharmacist provider status” law that recognizes pharmacists as 
providers for billing purposes.154 Most Oregon pharmacists have a National 
Provider Identification number to bill for immunizations, and the state has also 
established a billing pathway for them to get reimbursed for hormonal 
contraceptives.155 They will be reimbursed at the same rate as other 
prescribers.156 Patients with valid insurance will pay nothing or at least a reduced 
cost for their prescriptions, depending on their insurance coverage. If a patient is 
determined not eligible for hormonal contraceptive prescription and is referred 
to a physician, then the pharmacist will not charge insurance for the services.157 
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Thus, patients likely will not have excessive financial burden when obtaining 
hormonal contraceptives prescribed by pharmacists. 
Therefore, there is evidence that increasing access to hormonal 
contraceptives reduces unintended pregnancies, and thereby, costs for the health 
care system. In Oregon, since hormonal contraceptive prescriptions from 
pharmacists will be covered by insurance, patients with valid insurance will pay 
nothing or a reduced cost for their prescriptions. 
V.  CONCLUSION 
There is a distinction between the power of the FDA and states regarding 
protection of the public. The FDA has authority to regulate medical products, 
which allows it to be actively involved at every step of their approval process. 
The states have the authority to regulate the practice of health care professionals, 
because this power has been granted to them by the Fourteenth Amendment and 
has been acknowledged by the Supreme Court of the United States.  
Oregon, and states in general, is in a better position than the FDA to regulate 
the practice of health care professionals. First, Oregon will be able to respond to 
local access needs of its citizens more quickly than the FDA. Second, Oregon 
can enact laws that will allow health care professionals to address clinical needs 
of individual patients better than the FDA. Third, Oregon can enforce 
regulations and supervise the practice of health care professionals more closely 
and effectively than the FDA. 
This Article has shown that Oregon’s model offers strong solutions that 
likely resolves all concerns of the legal and medical communities. Oregon’s law 
will increase access to hormonal contraceptives. The clinical studies have shown 
that allowing pharmacists to prescribe hormonal contraceptives actually 
increases access to them, because women are willing and feel safe to receive 
hormonal contraceptive prescriptions from pharmacists. Oregon’s law will not 
jeopardize safety of women’s health; rather it will improve their health. The 
clinical studies have proved that pharmacists can prescribe medications safely, 
in fact, better than physicians can. Oregon’s law will not increase costs for 
patients and for the health care system. The studies have shown that increasing 
access to hormonal contraceptives reduces unintended pregnancy and abortion 
rates, which decreases overall health care costs. Also, with Oregon’s model, the 
cost for patients will not increase, because prescriptions from pharmacists will 
be covered by insurance and patients will pay nothing or receive a reduced cost 
for their prescriptions.  
Oregon’s model will serve as a prime example of a state’s effort in 
regulating the practice of health care professionals. Oregon’s efforts likely will   
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
390 SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY [Vol. 12:367 
inspire other states to expand the scope of the practice of pharmacists and 
empower pharmacists to enhance health care in the country. 
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